About Karyopharm
Karyopharm is a company based in Natick (United States) founded in 2008 by Sharon Shacham.. Karyopharm has raised $98.4 million across 11 funding rounds from investors including New Leaf Venture Partners, Marshall Wace and Citadel. The company has 279 employees as of December 31, 2024. Karyopharm offers products and services including SINE Technology and XPO1 Inhibition. Karyopharm operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Natick, United States
- Employees 279 as on 31 Dec, 2024
- Founders Sharon Shacham
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Karyopharm Therapeutics Inc.
-
Annual Revenue
$145.24 M-0.55as on Dec 31, 2024
-
Net Profit
$-76.42 M46.6as on Dec 31, 2024
-
EBITDA
$-119.1 M7.68as on Dec 31, 2024
-
Total Equity Funding
$98.4 M (USD)
in 11 rounds
-
Latest Funding Round
$8.75 M (USD), Post-IPO
Oct 08, 2025
-
Investors
New Leaf Venture Partners
& 12 more
-
Employee Count
279
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Karyopharm
Karyopharm is a publicly listed company on the NASDAQ with ticker symbol KPTI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Karyopharm
Karyopharm offers a comprehensive portfolio of products and services, including SINE Technology and XPO1 Inhibition. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits nuclear export to target oncogenesis in various tumor types.
Technology addressing fundamental cancer cell mechanisms through research.
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Finance and Accounting
10 people
Senior Team
7 people
Operations Team
7 people
Sales and Marketing
6 people
Human Resources and Administration
6 people
Software Development Team
4 people
Legal and Compliance
4 people
Unlock access to complete
Funding Insights of Karyopharm
Karyopharm has successfully raised a total of $98.4M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.75 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $8.8M
-
First Round
First Round
(05 Nov 2010)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Karyopharm | Valuation |
investors |
|
| Dec, 2022 | Amount | Post-IPO - Karyopharm | Valuation |
investors |
|
| Oct, 2018 | Amount | Post-IPO - Karyopharm | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Karyopharm
Karyopharm has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, Marshall Wace and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-short equity strategies are managed through specialized hedge funds.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Karyopharm
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Karyopharm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Karyopharm Comparisons
Competitors of Karyopharm
Karyopharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Karyopharm
Frequently Asked Questions about Karyopharm
When was Karyopharm founded?
Karyopharm was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Where is Karyopharm located?
Karyopharm is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Is Karyopharm a funded company?
Karyopharm is a funded company, having raised a total of $98.4M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $22.5M, raised on Nov 05, 2010.
How many employees does Karyopharm have?
As of Dec 31, 2024, the latest employee count at Karyopharm is 279.
What is the annual revenue of Karyopharm?
Annual revenue of Karyopharm is $145.24M as on Dec 31, 2024.
What does Karyopharm do?
Founded in 2008 and based in Natick, United States, small molecule drugs are developed by the company to address cancer and inflammatory diseases. These drugs target the nuclear pore complex to modulate key pathways involved in cell proliferation, inflammation, and nuclear-cytoplasmic protein transport. Operations focus on oncology and immunology sectors, with research centered on therapeutic interventions for unmet medical needs in these areas.
Who are the top competitors of Karyopharm?
Karyopharm's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Karyopharm offer?
Karyopharm offers SINE Technology and XPO1 Inhibition.
Is Karyopharm publicly traded?
Yes, Karyopharm is publicly traded on NASDAQ under the ticker symbol KPTI.
Who are Karyopharm's investors?
Karyopharm has 13 investors. Key investors include New Leaf Venture Partners, Marshall Wace, Citadel, Adage Capital Management, and Armistice Capital.
What is Karyopharm's ticker symbol?
The ticker symbol of Karyopharm is KPTI on NASDAQ.